Cargando…

Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies

T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma. Despite the reported exciting clinical results, the CAR-T cell approach needs efforts to impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guercio, Marika, Manni, Simona, Boffa, Iolanda, Caruso, Simona, Di Cecca, Stefano, Sinibaldi, Matilde, Abbaszadeh, Zeinab, Camera, Antonio, Ciccone, Roselia, Polito, Vinicia Assunta, Ferrandino, Francesca, Reddel, Sofia, Catanoso, Maria Luigia, Bocceri, Emilia, Del Bufalo, Francesca, Algeri, Mattia, De Angelis, Biagio, Quintarelli, Concetta, Locatelli, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560965/ https://www.ncbi.nlm.nih.gov/pubmed/34737753 http://dx.doi.org/10.3389/fimmu.2021.755639

Ejemplares similares

Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts
por: Quintarelli, Concetta, et al.
Publicado: (2021)

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
por: Caruso, Simona, et al.
Publicado: (2022)

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
por: Guercio, Marika, et al.
Publicado: (2020)

Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
por: Quintarelli, Concetta, et al.
Publicado: (2018)

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies
por: Manni, Simona, et al.
Publicado: (2023)

Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy
por: Pellegrino, Marsha, et al.
Publicado: (2020)

Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
por: Quintarelli, Concetta, et al.
Publicado: (2021)

Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
por: Nguyen, Phuong, et al.
Publicado: (2020)

Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma
por: Tumino, Nicola, et al.
Publicado: (2021)

The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors
por: Del Baldo, Giada, et al.
Publicado: (2023)

GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
por: Caforio, Matteo, et al.
Publicado: (2021)

T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies
por: Pulvirenti, Federica, et al.
Publicado: (2022)

CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies
por: Antonucci, Laura, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Motor Cars for Doctors: Cars Suitable for Practitioners
Publicado: (1906)

CERN cars at car sharing point on the Meyrin site
por: Andrade, Rui
Publicado: (2022)

Motor Cars for Doctors: Hints on Buying a Car
Publicado: (1906)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Car Club
por: Automobile Club
Publicado: (2012)

Car Club
por: Automobile club
Publicado: (2013)

CAR CLUB
por: Car Club
Publicado: (2012)

Car Observations
Publicado: (1859)

Eating in the Cars
Publicado: (1871)

Riding in the Cars
por: Weybridge, W.
Publicado: (1860)

Eating in the Cars
Publicado: (1885)

Reading on the Cars
Publicado: (1872)

Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells
por: Polito, Vinicia A., et al.
Publicado: (2019)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing
por: Ingegnere, Tiziano, et al.
Publicado: (2019)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Changes in private car ownership associated with car sharing: gauging differences by residential location and car share typology
por: Jain, Taru, et al.
Publicado: (2021)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rrglqp8vbb2ks7kvec4v36hu0k